The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N05 | Psycholeptics | |
| 3 | N05A | Antipsychotics | |
| 4 | N05AB | Phenothiazines with piperazine structure | |
| 5 | N05AB02 | Fluphenazine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 10 mg |
| PAREN - Parenteral (depot) | 1 mg |
| Active Ingredient | Description | |
|---|---|---|
| Fluphenazine |
Fluphenazine is an ester of the potent neuroleptic fluphenazine, a phenothiazine derivative of the piperazine type. The ester is slowly absorbed from the intramuscular site of injection and is then hydrolysed in the plasma to the active therapeutic agent, fluphenazine. It is used for the treatment and maintenance of schizophrenic patients and those with paranoid psychoses. |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
